What Can Brazil’s Pharma Industry Learn from India?
The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to reduce dependence on API imports from…
Tagged with Drug
Xavier De Cuyper – CEO, Belgian Federal Agency for…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare…
Orphan Drugs: Building the Regulatory Framework in the Czech…
A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s…
David López García – Country Manager, BioMarin Mexico
David López García, Mexico country manager of global rare genetic therapy player Biomarin, outlines the challenging situation around patient access…
The New Belgian Act on Medicinal Product Shortages
On 3 February 2020 the Act of 20 December 2019 amending various legal provisions concerning shortages of medicinal products was published in…
Rafael Gual Cosío – Director General, CANIFARMA, Mexico
Rafael Gual Cosío, director general of the Cámara Nacional de la Industria Farmacéutica (CANIFARMA), the umbrella industry association for the…
Tamás Demeter – Country Manager, AOP Orphan, Hungary
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP…
Jan Krejčí – Country Manager, Ewopharma, Czech Republic
Ewopharma’s Jan Krejčí, Country Manager for the Czech affiliate for the last eight years, shares the achievements of the company in its two main…
Czech Drug Shortages: Both Local & International Solutions…
Medicine shortages are a European-wide issue. In 2016, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) formed a task…
Myriam Hakim – General Manager GCC, Kyowa Kirin
Myriam Hakim, the recently appointed GM for Japanese specialty pharma firm Kyowa Kirin’s UAE affiliate, discusses the strategic significance of the…
FDA Drugs Approved in 2019
In 2019, the US FDA's Center for Drug Evaluation and Research approved 42 novel drugs, down from 59 drugs approved in 2018. Novartis had four drugs…
Mike Chen – President and CEO, ACROBiosystems, China
Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and…
